177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 48, Issue 1, 2021, Pages 152-160

  Paganelli, Giovanni ^a   Sansovini, Maddalena ^a   Nicolini, Silvia ^a   Grassi, Ilaria ^a   Ibrahim, Toni ^a   Amadori, Elena ^a   Di Iorio, Valentina ^a   Monti, Manuela ^a   Scarpi, Emanuela ^a   Bongiovanni, Alberto ^a   Altini, Mattia ^a   Urso, Luca ^b   Cittanti, Corrado ^b   Matteucci, Federica ^a   Severi, Stefano ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

177Lu DOTA octreotate; GI NET; Long term follow up; Overall survival; PRRT; Tumor burden

Indexed keywords

ANTINEOPLASTIC AGENT; KI 67 ANTIGEN; PENTETREOTIDE; RADIOISOTOPE; TETRAACETIC ACID OCTREOTATE LU 177; UNCLASSIFIED DRUG; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGE; AGED; ARTICLE; CANCER SIZE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; LIVER CANCER; MALE; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVERALL SURVIVAL; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIOISOTOPE THERAPY; CLINICAL TRIAL; GASTROINTESTINAL TUMOR; NEUROENDOCRINE TUMOR;

AGED; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; NEUROENDOCRINE TUMORS; OCTREOTIDE; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS;

EID: 85085574196     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-020-04873-0     Document Type: Article

References (24)

1. Pavel M, O’Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172–85. 10.1159/000443167. DOI: 10.1159/000443167
2. Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17:909–18. 10.1677/ERC-10-0152. DOI: 10.1677/ERC-10-0152
3. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am. 2011;40:1–18, vii. 10.1016/j.ecl.2010.12.005. DOI: 10.1016/j.ecl.2010.12.005
4. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72. 10.1200/JCO.2007.15.4377. DOI: 10.1200/JCO.2007.15.4377
5. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42. 10.1001/jamaoncol.2017.0589. DOI: 10.1001/jamaoncol.2017.0589
6. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. NETTER-1 Trial Investigators. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35. 10.1056/NEJMoa1607427. DOI: 10.1056/NEJMoa1607427
7. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]ocreotate: toxicity, efficacy and survival. J Clin Oncol. 2008;26(13):2124–30. 10.1200/JCO.2007.15.2553. DOI: 10.1200/JCO.2007.15.2553
8. Severi S, Grassi I, Nicolini S, Sansovini M, Bongiovanni A, Paganelli G. Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. Onco Targets Ther. 2017;10:551–7. 10.2147/OTT.S97584. DOI: 10.2147/OTT.S97584
9. 177Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Eur J Nucl Med Mol Imaging. 2014;41(10):1845–51. 10.1007/s00259-014-2735-5. DOI: 10.1007/s00259-014-2735-5
10. Bosman F, Carneiro F, editors. World Health Organization classification of tumours, pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2010.
11. Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-Fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16(3):978–85. 10.1158/1078-0432.CCR-09-1759. DOI: 10.1158/1078-0432.CCR-09-1759
12. 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(6):881–8. 10.1007/s00259-013-2369-z. DOI: 10.1007/s00259-013-2369-z
13. Bahri H, Laurence L, Edeline J, Leghzali H, Devillers A, Raoul JL, et al. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation. J Nucl Med. 2014;55(11):1786–90. 10.2967/jnumed.114.144386. DOI: 10.2967/jnumed.114.144386
14. 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35(10):1847–56. 10.1007/s00259-008-0778-1. DOI: 10.1007/s00259-008-0778-1
15. Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 1Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38(12):2125–35. 10.1007/s00259-011-1902-1. DOI: 10.1007/s00259-011-1902-1
16. Capdevila J, Hernando J, Perez-Hoyos S, Roman-Gonzalez A, Grande E. Meta-analysis of randomized clinical trials comparing active treatment with placebo in metastatic neuroendocrine tumors. Oncologist. 2019;24(12):e1315–20. DOI: 10.1634/theoncologist.2018-0675
17. 177Lu-D OTATATE. Eur J Nucl Med Mol Imaging. 2017;44(3):490–9. 10.1007/s00259-016-3533-z. DOI: 10.1007/s00259-016-3533-z
18. Ngo H, Tortorella SM, Ververis K, Karagiannis TC. The Warburg effect: molecular aspects and therapeutic possibilities. Mol Biol Rep. 2015;42(4):825–34. 10.1007/s11033-014-3764-7. DOI: 10.1007/s11033-014-3764-7
19. Claringbold PG, Brayshaw PA, Price RA, Turner JH. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 38(2):302–11. 10.1007/s00259-010-1631-x.
20. Veenendaal LM, Borel Rinkes IHM, Lips CJM, van Hillegersberg R. Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy. World J Surg Oncol. 2006;4:35. 10.1186/1477-7819-4-35. DOI: 10.1186/1477-7819-4-35
21. 177Lu-octreotate. J Nucl Med. 2014;55(2):183–90. 10.2967/jnumed.113.125336. DOI: 10.2967/jnumed.113.125336
22. Panzuto F, Merola E, Pavel ME, Rinke A, Kump P, Partelli S, et al. Stage IV gastro-entero-pancreatic neuroendocrine neoplasms: a risk score to predict clinical outcome. Oncologist. 2017;22(4):409–15. 10.1634/theoncologist.2016-0351. DOI: 10.1634/theoncologist.2016-0351
23. Bertani E, Fazio N, Radice D, Zardini C, Spinoglio G, Chiappa A, et al. Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation. Eur J Surg Oncol. 2017;43(2):372–9. 10.1016/j.ejso.2016.09.011. DOI: 10.1016/j.ejso.2016.09.011
24. Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptidereceptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology. 2017;105(3):295–309. 10.1159/000475526. DOI: 10.1159/000475526